Brentuximab vedotin (SGN-35) is currently in a phase II single-agent clinical trial for patients with relapsed or refractory systemic ALCL.

For more information about brentuximab vedotin, click on the link to the left. You may also click on the link below to go directly to the clinicaltrials.gov web site for more details about this clinical trial.

A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

For general information about clinical trials, click on the About Clinical Trials page to the left.